Oxford Medical Products is a technology company.
Oxford Medical Products has raised $5.0M across 2 funding rounds.
Oxford Medical Products has raised $5.0M in total across 2 funding rounds.
Oxford Medical Products is a UK-based biotechnology company developing non-invasive weight management solutions and gastroretentive drug delivery systems.[1][2] Its lead product, Sirona, is an oral hydrogel capsule that expands in the stomach to suppress appetite mechanically, mimicking surgical effects without pharmacology, targeting patients with obesity (BMI 30–40 kg/m²).[1][2][4][7] The company serves the healthcare and pharmaceutical sectors, addressing unmet needs in affordable weight loss alternatives to surgery or GLP-1 drugs, with $4.84M raised across seed VC rounds and positive Phase 2 safety data from UK NHS trials as of March 2025.[1][7] It also advances OMP-GEL for sustained drug and nutraceutical delivery.[2]
Oxford Medical Products was incorporated on December 17, 2016, as JAMCOWP01 Limited, renaming to its current form by March 2019, with operations starting in 2017 from Witney, England.[1][5] The idea emerged from collaboration between Professor Jan Czenurska, a hydrogel expert, and Dr. Hutan Ashrafian, a bariatric surgeon, who combined expertise to create a non-invasive weight loss solution.[3] Dr. Camilla Easter (CEO) and Dr. Nick Edwards, medically trained entrepreneurs, joined to commercialize it, forming a team of scientists, surgeons, and business leaders.[2][3] Early traction included preclinical development of the self-expanding capsule, patents in anorectics, dosage forms, and drug delivery (3 filed), and progression to late-stage human trials.[1][3]
Oxford Medical Products rides the obesity treatment boom, where GLP-1 drugs exceed $30B forecasts but face side effects, adherence issues, and high costs, creating demand for non-drug alternatives.[7] Timing aligns with multidisciplinary obesity management trends—drug-device hybrids for maintenance post-GLP1—amid rising global overweight rates (over two-thirds in developed world).[3][7] Favorable market forces include regulatory push for non-invasive options and biotech/medtech convergence, with OMP's gastroretentive tech enabling better oral delivery for metabolic drugs.[2][4][7] It influences the ecosystem by partnering with pharma for API delivery, potentially expanding hydrogel applications to nutraceuticals/biosensors, challenging device firms like Allurion.[1][2][7]
Oxford Medical Products is poised for pivotal Phase 3 trials in Q2 2025, potentially accelerating partnerships or exits amid obesity market growth.[7] Trends like GLP-1 combination therapies and oral bioavailability improvements will shape its path, with OMP-GEL targeting anti-obesity/metabolic drugs.[2][7] Its influence may evolve from niche weight loss innovator to platform provider, disrupting with safe, scalable mechanics if trial data sustains momentum—echoing its origin as a surgery alternative now ready to scale globally.[1][3][7]
Oxford Medical Products has raised $5.0M in total across 2 funding rounds.
Oxford Medical Products's investors include Ada Ventures, C4 Ventures, Index Ventures, Octopus Ventures, Playfair Capital, Ben Holmes, Mandeep Singh, Robin Klein.
Oxford Medical Products has raised $5.0M across 2 funding rounds. Most recently, it raised $3.0M Venture Round in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2022 | $3.0M Venture Round | Ada Ventures | |
| Mar 1, 2021 | $2.0M Seed | Ada Ventures, C4 Ventures, Index Ventures, Octopus Ventures, Playfair Capital, Ben Holmes, Mandeep Singh, Robin Klein |